Cancer research continues to make progress across several areas, including treatment development, early detection and understanding how patients experience life after diagnosis. Advances in medical research are contributing to new approaches to tackling the disease, while also raising questions about treatment outcomes, long-term health and quality of life.
One area attracting attention is the development of new treatments for pancreatic cancer, which remains one of the more difficult cancers to detect and treat. Research into daraxonrasib, an investigational oral drug, has reported improved survival outcomes compared with traditional chemotherapy in patients with advanced pancreatic cancer. Clinical trial findings indicated that half of the patients receiving the drug lived for at least 13 months, compared with less than seven months among those receiving chemotherapy.
The findings could provide another treatment option for patients with limited alternatives, although the drug remains under investigation. Research into targeted treatments could also have wider applications for other cancers driven by similar genetic mutations.
Improvements in cancer detection are also helping identify disease at earlier stages. New screening approaches include blood-based tests and at-home stool tests designed to identify DNA and RNA markers associated with colorectal cancer. These developments could expand screening options and make testing more accessible, although colonoscopy remains the established standard for detecting colorectal cancer.
Artificial intelligence is another area attracting increasing attention within cancer research. Researchers are investigating how AI can analyse complex genetic and clinical information to identify treatments that are better matched to individual patients. AI-guided robotic systems are also being developed to support surgical procedures, with the potential to improve accuracy, reduce complications and shorten recovery periods.
Immunotherapy continues to influence treatment approaches across several cancer types, including melanoma, lung cancer, liver cancer and multiple myeloma. Rather than relying solely on conventional chemotherapy, these treatments work by helping the body’s immune system recognise and attack cancer cells. Approaches include immune checkpoint inhibitors, monoclonal antibodies and newer forms of cellular therapy.
CAR T-cell, tumour-infiltrating lymphocyte and natural killer cell treatments are also being investigated for a wider range of cancers. These approaches involve using immune cells to target cancer, with researchers working to improve their effectiveness against solid tumours.
Biotech Growth Trust plc (LON:BIOG) seeks capital appreciation through investment in the worldwide biotechnology industry. The Company and the Company’s Portfolio Manager believe that there is a high congruence between companies that seek to act responsibly and those that succeed in building long-term shareholder value.
